Will CBD show up on a drug test in South Africa?
Pure CBD doesn’t trigger a standard SA workplace drug test — but trace-THC CBD products can. How tests actually work, what 0.001% and 0.075% THC labels mean in practice, and how to choose a low-risk product. Updated May 2026.
The honest answer most pages dance around: pure CBD does not show up on a standard SA workplace drug test, because workplace tests look for THC and its metabolite (THC-COOH), not for CBD itself. But many products sold as “CBD” in South Africa contain trace THC — and that trace can, in some cases, trigger a positive. Here is what actually matters.
How drug tests in SA workplaces actually work
- Screening — immunoassay. A urine sample is tested against antibodies that bind THC-COOH (not CBD). Standard cut-off for screening is around 50 ng/mL of THC-COOH. Below the cut-off → negative.
- Confirmation — GC-MS or LC-MS/MS. A positive screen is supposed to go to confirmatory testing, which separates the molecules unambiguously. The confirmation cut-off is typically 15 ng/mL. Without this step the screen alone is not reliable for dismissal — see our workplace-cannabis guide.
CBD product types ranked by test risk
- CBD isolate — cannabidiol only, no THC, no other cannabinoids. Test risk: essentially zero on a standard panel.
- Broad-spectrum CBD — multiple cannabinoids and terpenes with THC removed below detection. Test risk: very low in practice; check the Certificate of Analysis (COA) for the THC line item.
- Full-spectrum CBD — whole cannabinoid profile including trace THC. Test risk: small but real, especially at chronic high doses (200 mg+/day for long periods).
- Adult-use cannabis flower / vapes / edibles (regardless of how a shop frames it) — high THC content; will test positive.
What “0.001% THC” and “0.075% THC” on a label mean
South African Schedule-0 labelling under Gazette 43347 of 2020 allows a CBD product to be sold over-the-counter provided THC stays below a defined trace. In practice you will see two figures in the market:
- < 0.001% THC — the strictest trace, often associated with isolate and well-processed broad-spectrum products. Almost no realistic test risk.
- < 0.075% THC — the upper Schedule-0 trace threshold. Legal, but at chronic high daily doses there is a small non-zero risk of triggering a screen.
Always read the actual product COA, not just the front label. See our COA reading guide.
How to pick a low-risk CBD product for a tested workplace
- Prefer isolate or broad-spectrum.
- Look for a published per-batch COA, not a generic data sheet.
- Cross-check the THC line item — not just total cannabinoids.
- If you take a daily dose, do the maths: dose × days = total THC exposure. At very high cumulative exposure even “non-detect” labels can stack into something detectable.
Edge cases worth knowing
- Chronic high-dose users. Daily 200 mg+ of full-spectrum CBD over months can build trace THC in fat tissue. For tested workplaces, drop to broad-spectrum or isolate.
- Contamination. Some low-quality CBD products test higher in THC than labelled. The defence is a published per-batch COA you have actually read.
- Second-hand smoke. Real but small; needs prolonged close exposure in a poorly-ventilated space to register.
If you’re a competitive athlete
WADA removed CBD itself from its prohibited list in 2018, and SAIDS aligns with WADA. THC remains prohibited in-competition. A clean Schedule-0 CBD product (THC < 0.001%) should not test you positive; a full-spectrum at the upper trace can. For training and recovery guidance see our recovery wellness page.